Advanced non-small cell lung cancer
Conditions
Interventions
Index test:Information of the device to be evaluated:
1. Product name: software for sequencing data analysis of circulating tumor DNA gene mutations
2. Model specification: BRTMAS-CTDNA
3. Manufacturer: Guangzhou Burning Rock Dx Co., Ltd.
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Sign a written informed consent to participate in the study; 2. Aged 18 and above; 3. Patients with advanced non-small cell lung cancer (NSCLC) or small cell lung cancer confirmed by histology or cytology; 4. Sample collection shall meet the following requirements: (1) Peripheral blood can be collected with a sample size of 8-10ml. (2) Blood collection should be completed before the first targeted therapy for patients who are newly treated or have not previously received targeted therapy; (3) After treatment, blood collection should be completed before the beginning of the next line treatment; (4) Tissue is accessible and sufficient matching paraffin-embedded tumor tissue samples (FFPE) can be obtained at the same time as blood samples (such as samples taken at treatment baseline or samples taken after first-line targeted therapy resistance), and the proportion of tumor cells assessed by pathology is not less than 20%.
Exclusion criteria
Exclusion criteria: 1. The samples are contaminated or suspiciously contaminated, or there is a lot of hemolysis and lipemia in the samples; 2. Patients who have received allogeneic blood transfusion or other treatments that may introduce foreign DNA within 3 months; 3. Plasma was not separated from peripheral blood samples within the specified time; 4. Tissue samples cannot meet testing requirements (such as insufficient tissue samples, lost wax blocks, etc.); 5. Repeated sampling from the same case; 6. Exceeding number of cases (competing for inclusion); 7. The basic information of the sample is incomplete (including but not limited to the tracing ID number of the subject, pathological diagnosis/clinical diagnosis and clinical stage), and is not standardized, such as lack of key tracing information and unclear diagnostic information, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Advanced non-small cell lung cancer gene; | — |
Countries
China
Contacts
Public ContactTang Yuan, Lu You
West China Hospital, Sichuan University
Outcome results
None listed